Jie Liu

Jie Liu

Auto-generated profile, based on publicly available information

Jie Liu

The Graduate School of Fujian Medical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
Rui LiuRui Liu
Rui Liu
JLJie Liu
Jie Liu
QCQiang Cao
Qiang Cao
YCYanpeng Chu
Yanpeng Chu
HCHao Chi
Hao Chi
BLBo Li
Bo Li
Background: To explore the hub gene closely related to the progression of gastric cancer (GC), so as to provide a theoretical basis for revealing the therapeutic mechanism of GC.

14 November 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JLJie Liu
Jie Liu
XWXujin Wei
Xujin Wei
YXYixuan Xie
Yixuan Xie
YYYuxiang Yan
Yuxiang Yan
SXSihui Xue
Sihui Xue
QHQingling Huang
Qingling Huang
MDM4 is one of the major regulators of p53. The biological effect of MDM4 on tumor is controversial, its role and molecular mechanism in colon cancer progression and prognosis are still unclear. In this study, we identify that MDM4 is significantly overexpressed in human colon cancer and high MDM4 expression was associated with poor prognosis of colon cancer with mutant p53. MDM4 inhibits the ubiquitination of the ferroptosis marker protein GPX4 at K167 and K191 by upregulating the protein expression level of the E3 ubiquitin ligase TRIM21, which promotes the polyubiquitination of GPX4 transfer from K48- to K63- linked ubiquitination. Thereby, MDM4 enhances the stability of GPX4 protein, inhibiting ferroptosis, increasing the resistance of colon cancer patients to chemotherapy, and promoting colon cancer progression. These findings elucidate the ferroptosis inhibition effect of MDM4 via regulating TRIM21/GPX4 on p53-mutated colon cancer and provide a potential therapeutic strategy for colon cancer therapy.

3 May 2023 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
JLJie Liu
Jie Liu
KZKe Zhao
Ke Zhao
SZSiyao Zhou
Siyao Zhou
LHLan Hong
Lan Hong
YXYao Xu
Yao Xu
ZCZhengmao Cai
Zhengmao Cai
Background: Suicidal ideation is common among people diagnosed with schizophrenia spectrum disorders and may be related to neurocognitive, social cognitive, and clinical variables. This study aimed to investigate the relationships between suicidal ideation and both neurocognitive function and empathy. Methods: The sample for this cross-sectional study comprised 301 schizophrenic patients aged 18–44 years. All participants were administered the Beck Scale for Suicide Ideation—Chinese Version (BSI—CV), the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Interpersonal Reactivity Index (IRI), and the Positive and Negative Syndrome Scale (PANSS). The demographic and clinical data of the patients were also collected. Results: In total, 82 patients reported suicidal ideation. Compared to patients without suicidal ideation, patients with suicidal ideation showed significant differences in the IRI-Personal Distress subscale, PANSS-General Psychopathology symptom scores, and suicide attempts. Moreover, there were moderating effects of neurocognitive function and empathy on the relationship between suicide attempts and suicidal ideation. Conclusions: These results indicate that the personal distress component of empathy, general psychopathology symptoms and suicide attempts are independent risk factors for suicidal ideation in Chinese adults with schizophrenia. Moreover, neurocognitive function may also be related to suicidal ideation through a moderating relationship. In order to reduce suicidal ideation among patients with schizophrenia, early screening of empathy and neurocognitive function is essential.

7 October 2024 in eLife
Verified
Journal Article
Open access
XWXujin Wei
Xujin Wei
JLJie Liu
Jie Liu
JCJia Cheng
Jia Cheng
WCWangyu Cai
Wangyu Cai
WXWen Xie
Wen Xie
HZHuiqin Zhuo
Huiqin Zhuo
Gastric cancer (GC) is a major cause of cancer-related mortality worldwide. Despite the widespread recognition of tumor immunotherapy in treating unresectable GC, challenges, including ineffective immunotherapy and drug resistance, persist. Therefore, understanding the regulatory mechanisms of PD-L1, particularly in the context of super-enhancers (SEs) and zinc finger protein 36 ring finger protein-like 1 (ZFP36L1) RNA-binding protein, is crucial. In this study, we performed H3K27ac Cleavage Under Targets and Tagmentation (CUT&Tag) sequencing, investigated the heterogeneity of SEs between two GC subtypes with differential growth patterns, and revealed the immune escape signatures driven by ZFP36L1-SE in infiltrative GC through SEs inhibitors treatment. The regulation of ZFP36L1 to PD-L1 was evaluated by quantitative PCR, western blot, flow cytometry, and immunohistochemistry. Furthermore, we explored its regulatory mechanisms using a combination of molecular biology techniques, including luciferase reporter assay, GST/RNA pull-down, chromatin immunoprecipitation (ChIP)/RIP experiments, and in vivo functional assays. We demonstrated that ZFP36L1, driven by an SE, enhances IFN-γ-induced PD-L1 expression, with SPI1 identified as the specific transcription factor binding to ZFP36L1-SE. Mechanistically, ZFP36L1 binds to the adenylate uridylate-rich element in the 3ʹ untranslated region (3ʹUTR) of HDAC3 mRNA, exacerbating its mRNA decay, and thereby facilitating PD-L1 abnormal transcriptional activation. Collectively, our findings provide mechanistic insights into the role of the SPI1-ZFP36L1-HDAC3-PD-L1 signaling axis in orchestrating immune escape mechanisms in GC, thereby offering valuable insights into the potential targets for immune checkpoint therapy in GC management.

7 November 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
HCHan Chen
Han Chen
QPQilong Pan
Qilong Pan
MMMeiqi Mao
Meiqi Mao
WLWu Lin
Wu Lin
SYSisi Yan
Sisi Yan
QHQingling Huang
Qingling Huang
MDMX serves as a significant regulator of p53, which is a crucial tumor suppressor protein. However, the biological functions and underlying mechanism of MDMX in hepatocellular carcinoma (HCC) remain inadequately understood. In this study, we demonstrate that MDMX is overexpressed in HCC, and elevated expression of MDMX is significantly correlated with poor prognosis in HCC harboring mutant p53. MDMX inhibits the degradation of 14-3-3γ and facilitates its localization within cytoplasm, thereby enhances the interaction between FOXO1 and 14-3-3γ, which promotes the degradation of FOXO1. Consequently, the overexpression of MDMX results in downregulation of FOXO1 followed by increase of RPIA and decrease of PCK1, leading to increased glucose uptake, lactate secretion, and ATP production. These findings elucidate the role of MDMX in promoting glycolysis through the regulation of the 14-3-3γ/FOXO1 axis in p53-mutated HCC, thereby offering a potential therapeutic target for the treatment of HCC.

1 October 2020 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
JCJoshua C. Chao
Joshua C. Chao
YQYanmei Qi
Yanmei Qi
JLJie Liu
Jie Liu
MSMark P. Scheuerman
Mark P. Scheuerman
LLLeonard Y. Lee
Leonard Y. Lee
SLShaohua Li
Shaohua Li